Home | Welcome to Contract Pharma   
Last Updated Thursday, November 20 2014
Print

Hospira Makes Executive Changes



Published March 4, 2013
Royce R. Bedward has been appointed corporate vice president, general counsel and secretary, at Hospira, Inc. Mr. Bedward will oversee the company's legal department, including litigation, benefits, labor and employment, intellectual property, governance, securities and transactional matters. He will report to Brian Smith, who assumes the newly created role of chief legal officer, including responsibility for government affairs. Both Mr. Smith and Mr. Bedward will serve as members of the company's senior leadership team, led by F. Michael Ball, chief executive officer.
 
"Royce is an accomplished lawyer and integrity-driven business leader with more than 10 years of experience in the healthcare field and a proven track record of success at Hospira," said Mr. Ball. "We look forward to Royce's many additional contributions, while thanking Brian for his continued service and counsel. Working together, I'm confident that their strong leadership abilities will help position Hospira for a stronger future of sustainable, long-term growth and drive greater value for our stakeholders."
 
Mr. Bedward is one of the founding members of Hospira's legal leadership team, joining the company as vice president of litigation, and assuming roles of increasing responsibility, most recently as deputy general counsel and secretary. Prior to the company's spin-off from Abbott Laboratories, Mr. Bedward served as Abbott's senior counsel, litigation, where his practice included patent issues related to the Hatch-Waxman Act, defense of investigations, major commercial disputes, product liability matters and arbitrations.
 
Also, Sumant Ramachandra, M.D., Ph.D., is resigning from his position as senior vice president and chief scientific officer, effective March 8. Dr. Ramachandra has served in this role since 2008. The company has initiated a search for his successor.
 
Mr. Ball said, "On behalf of Hospira, I'd like to thank Sumant for his many contributions and wish him the best in his future endeavors. During his tenure, we have established one of the most robust biosimilars pipelines in the industry, expanded an already market-leading generic injectables portfolio and built a talented scientific, medical and regulatory organization to execute our vision for future success."


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On